SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending amidst heightened geopolitical tensions, primarily fueled by President Trump's recent rhetoric regarding Greenland and threats of substantial tariffs against European allies like France. The community is bracing for significant market volatility, with many predicting a "bloodbath" and actively discussing bearish positions, while others anticipate a "buy the dip" recovery. These concerns are amplified by broader instability in global financial markets, including surging bond yields in both the US and Japan.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is trending amid escalating geopolitical tensions and tariff threats from the US concerning Greenland, compounded by an anticipated Supreme Court decision related to tariffs, which has triggered a pre-market sell-off in tech-heavy indices. Community sentiment is sharply divided; while some anticipate a severe market downturn and "Black Tuesday," many others see this as a manufactured dip and a "buy the dip" opportunity, expecting a quick recovery. This dynamic reflects QQQ's sensitivity to global trade policy and broader economic uncertainties, despite ongoing tech sector narratives.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is experiencing significant buzz following its Saudi FDA approval for non-small cell lung cancer, signaling a potential paradigm shift in cancer treatment. The community is fiercely optimistic, citing high short interest, CEO Dr. Patrick Soon-Shiong's vocal advocacy against perceived FDA bureaucracy, and the company's mission to cure cancer as drivers for an anticipated massive short squeeze and substantial growth.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical (DRTS) is trending strongly, fueled by recent breakthrough pancreatic cancer data and high expectations surrounding its J.P. Morgan Healthcare Conference presentation. The community is abuzz with anticipation for imminent PMDA approval in Japan and rumored institutional buying, spotlighting Alpha Tau's innovative Alpha DaRT technology as a potentially undervalued and disruptive force in oncology. Significant trading volume reflects growing investor confidence and a belief that clinical milestones are poised to drive substantial upside, independent of broader market trends.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is heavily discussed due to its strong pivot towards becoming a major AI cloud infrastructure provider, significantly highlighted by a massive power and infrastructure deal with a prominent tech client. Community sentiment points to high expectations for additional large-scale AI/HPC partnerships, particularly given its substantial power capacity and strategic advantages in the booming compute sector. Investors are actively watching for further developments as the company solidifies its position beyond traditional crypto mining.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies is trending after its recent AGM, where a significant increase in authorized shares passed alongside the announcement of a $200 million investment in MrBeast Industries. This has fueled a polarized community discussion, with concerns over potential dilution and the company's strategic direction clashing against long-term bullish sentiment for its Ethereum treasury holdings. The controversy leaves many questioning the immediate impact on BMNR's perceived connection to Ethereum's performance.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending as investors are enthusiastic about recent confirmations of its Optical Interposer technology being utilized by major players like Marvell, acquired through Celestial AI. The community is actively discussing POET's role as a critical enabler for the AI and data center "optical supercycle" by offering high-density, low-power, and cost-effective optical interconnect solutions. Anticipation is high for upcoming customer and investor disclosures, though some perceive market manipulation hindering immediate price appreciation.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is experiencing significant upward momentum driven by strong preliminary Q4 results and an accelerated 2026 outlook, with IBSRELA revenue now projected to reach $1 billion by 2029. This bullish sentiment is further fueled by a patent extension for both IBSRELA and XPHOZAH until 2041, which the community sees as a 'game changer' fundamentally re-rating the company's long-term value and sparking widespread speculation about potential acquisition interest.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is actively trending, fueled by its aggressive expansion in the artificial intelligence sector, notably a new data center lease deal with RIOT Platforms to support significant AI workload capacity. The community is discussing AMD's strengthened position as a leading contender in high-performance AI, reinforced by analyst upgrades, including Wells Fargo naming it a top pick for 2026. This reflects broader market optimism around insatiable demand for data center computing, where AMD is carving out substantial growth.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is trending amidst a notable downturn, with community discussion centered on a resurfaced short report alleging fraudulent data practices and money laundering. Despite recent analyst upgrades highlighting its strong fundamentals and AI-driven ad platform, many investors are debating whether the sharp decline stems from market manipulation or presents a strategic buying opportunity ahead of upcoming earnings.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Context Therapeutics (NASDAQ:CNTX) Coverage Initiated by Analysts at Jones Trading

Jones Trading initiated coverage on Context Therapeutics in a research report on Monday. They issued a "buy" rating and a $7.00 price objective for the company...

Context Therapeutics Inc. (NASDAQ:CNTX) Given Average Recommendation of "Moderate Buy" by Brokerages

Context Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) has received an average recommendation of "Moderate Buy" from the nine brokerages that are covering the stock, Marketbeat.com reports. One...

Context Therapeutics (NASDAQ:CNTX) Upgraded to "Sell" at Wall Street Zen

Wall Street Zen upgraded Context Therapeutics to a "sell" rating in a report on Saturday...

Context Therapeutics (NASDAQ:CNTX) Earns "Buy" Rating from D. Boral Capital

D. Boral Capital reiterated a "buy" rating and issued a $9.00 target price on shares of Context Therapeutics in a research report on Thursday...

Context Therapeutics (NASDAQ:CNTX) Announces Earnings Results

Context Therapeutics (NASDAQ:CNTX - Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts...

Shares of Context Therapeutics Inc. rose over&nbsp;7% in Wednesday's pre-market trading after JMP Securities initiated coverage with an 'Outperform' rating and a price target of $4.&nbsp;The brokerage's target implies a near quadrupling from the stock's previous close and has fueled bullish sentiment among retail investors.In its research note, JMP highlighted Context's focus on developing next-generation T-cell-engaged bispecific antibody therapies for solid tumors.&nbsp;The micro-cap biotech is building a portfolio of in-licensed clinical-stage TCE bispecific antibodies, which the analyst described as "innovative."&nbsp;JMP also praised the management team's business development acumen in assembling a pipeline that it believes is “worth more than the sum of its parts.”Retail chatter on Stocktwits mirrored the analyst's enthusiasm, with one user predicting a move to $6 and another noting the stock could "come back in a hurry" after a period of limited news flow.<stembedurl>https://stocktwits.com/Leonkika/message/599089608</stembedurl><stembedurl>https://stocktwits.com/claybridge/message/598957638</stembedurl>Context Therapeutics' lead program, CTIM-76, is poised to enter clinical trials soon.&nbsp;According to D. Boral Capital, which issued a ‘Buy’ rating and a $9 price target in November, CTIM-76 targets Claudin 6, a tumor marker broadly expressed in solid tumors like gynecologic and testicular cancers but largely absent in healthy adult tissues.&nbsp;This specificity makes it a promising therapeutic target, the brokerage said.Context’s stock has lost over 8% over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

Context Therapeutics Stock Jumps Pre-Market On Analyst's Near 4x Upside View: Retail Pins High Hopes Too

The micro-cap biotech is building a portfolio of in-licensed clinical-stage TCE bispecific antibodies, which JMP described as "innovative”

Equity

The micro-cap biotech is building a portfolio of in-licensed clinical-stage TCE bispecific antibodies, which JMP described as "innovative”


Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. It engages in developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The firm's robust clinical program for candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. Its ONA-XR is a novel, first-in-class small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women?s cancers. The company was founded by Martin Lehr and Felix Kim in April 2015 and is headquartered in Philadelphia, PA.

CNTX
Context Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Latest CNTX News

CNTXContext Therapeutics Inc